16 reports

  • 2.7 Global Factor VIII Market
  • 2.7 Global Factor VIII Market
  • Factor VIII
  • World
  • CSL Limited
  • Grifols, S.A.
  • Shire plc
  • PFIZER IN GLOBAL FACTOR VIII MARKET
  • BAYER HEALTHCARE IN GLOBAL FACTOR VIII MARKET
  • Factor VIII
  • Baxalta Incorporated
  • Bayer AG
  • Biogen Idec Inc.
  • Grifols, S.A.
  • Gene therapy to activate factor IX for hemophilia B
  • Hemophilia Therapeutics, APAC, Management of Bleeding Episodes
  • Factor VIII
  • World
  • Market Size
  • Novo Nordisk Group
  • Pfizer Inc.

Factor VIII – Introduction ##.

  • Biopharmaceutical
  • Factor VIII
  • World
  • Demand

Factor VIII Inhibitor Bypassing Fraction – Introduction ##.

  • Biopharmaceutical
  • Factor VIII
  • World
  • Demand

Factor VIII / Von Willebrand factor – Introduction ##.

  • Biopharmaceutical
  • Factor VIII
  • World
  • Demand

Factors) Worldwide (2015) - Percentage Share Breakdown by Value for Asia-Pacific, Europe, North America and Others ## Table ##: Plasma Market by Region Worldwide (2014) - Percentage Share Breakdown by Value Sales for Asia, Europe, and Middle East, USA, and Others ## Table ##: Plasma Market

  • Biochemical
  • Blood Supply
  • Factor VIII
  • China
  • Market Shares
  • RECOMBINANT FACTOR VIII REPLACEMENT FOR HEMOPHILIA A - DRUG PROFILE
  • GENE THERAPY TO ACTIVATE FACTOR VIII FOR HEMOPHILIA A - DRUG PROFILE
  • Blood Disease
  • Factor VIII
  • United States
  • World
  • Product Initiative
  • 8.6 RECOMBINANT FACTOR VIII
  • NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR RECOMBINANT FACTOR VIII, BY COUNTRY, 2014-2021 (USD MILLION)
  • Factor VIII
  • Interferon
  • North America
  • World
  • JenKem Technology Co., Ltd
  • Clinical Trial profile. 145 Trial Title
  • Clinical Trial profile. 55 Trial Title
  • Blood Disease
  • Clinical Trial
  • Factor VIII
  • World
  • Product Initiative
  • Proportion of Von Willebrand Disease (Factor VIII Deficiency) to Hematological Disorders Clinical Trials, G7 Countries
  • Proportion of Von Willebrand Disease (Factor VIII Deficiency) to Hematological Disorders Clinical Trials, E7 Countries
  • Blood Disease
  • Factor VIII
  • Pathology
  • World
  • Product Initiative
  • GENE THERAPY TO ACTIVATE FACTOR VIII FOR HEMOPHILIA A - DRUG PROFILE
  • ANTIHEMOPHILIC FACTOR (RECOMBINANT) - DRUG PROFILE
  • Blood Disease
  • Factor VIII
  • United States
  • World
  • Product Initiative
  • Recombinant Protein to Replace Factor VIII for Hemophilia A
  • Pharming Group N.V. - Discovery, 2015
  • Blood Disease
  • Enzyme
  • Factor VIII
  • Transgenic
  • Pharming Group NV
  • MEAN PER CAPITA USAGE OF FACTOR VIII (2014)
  • GLOBAL FACTOR VIII MARKET SIZE, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • Factor VIII
  • Hospital
  • World
  • Market Size
  • Grifols, S.A.
  • Global Demand for Factor VIII by Type (2014E)
  • Global Demand for Factor VIII (2010-2016E)
  • Blood Disease
  • Factor VIII
  • World
  • Forecast
  • Novo Nordisk Group
  • CP3000 - FACTOR VIII
  • CP3000 - Factor VIII - Product Status
  • Factor VIII
  • In Vitro Diagnostic Reagent
  • United States
  • Product Initiative
  • Sekisui Chemical Group